Crossmark

Clinical insights on “Effectiveness and safety of ravulizumab for Japanese patients with atypical hemolytic uremic syndrome (aHUS) switched from eculizumab”

Crossref DOI link: https://doi.org/10.1007/s10157-025-02737-1

Published Online: 2025-07-15

Published Print: 2025-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Karim, Ali

Rida, FNU

Omoijuanfo, Ekata Agnes

Irshad, Noor un nisa https://orcid.org/0009-0006-1584-5024
Soomro, Abdul Karim

Muhammad, Faqeer
License Information

Text and Data Mining valid from 2025-07-15

Version of Record valid from 2025-07-15
More Information

Article History

Received: 5 July 2025

Accepted: 7 July 2025

First Online: 15 July 2025

Declarations

:

: The authors declare that they have no conflict of interest.

: Not applicable.

: Not applicable.

: Not applicable.

Document is current

Any future updates will be listed below